Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 5/20 | 0.39 |
| ▸ | HTR2C | P28335 | 7/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.38 |
| ▸ | GLS | O94925 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.34 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20169433 | 0.83 | GLS (0.39) | MCHR1HTR2CSLC6A4GLSHTR2A | |
| SCHEMBL17539114 | 0.79 | GLS (0.37) | MCHR1HTR2CSLC6A4GLSHTR2A | |
| SCHEMBL17539151 | 0.79 | HTR2C (0.35) | MCHR1HTR2CSLC6A4GLSHTR2A | |
| SCHEMBL12152325 | 0.77 | TSHR (0.54) | HTR2CSLC6A4GLSPDK2DRD2 | |
| SCHEMBL1935308 | 0.75 | PPARG (0.46) | HTR2CSLC6A4GLSCACNA1BCTSL | |
| SCHEMBL17539082 | 0.75 | GPR119 (0.41) | MCHR1HTR2CSLC6A4GLSPDK2 | |
| SCHEMBL17509604 | 0.75 | GPR119 (0.41) | MCHR1HTR2CSLC6A4GLS | |
| SCHEMBL17509620 | 0.74 | GLS (0.39) | MCHR1HTR2CSLC6A4GLSHTR2A | |
| SCHEMBL17509606 | 0.74 | HTR2C (0.37) | MCHR1HTR2CSLC6A4GLSPDK2 | |
| SCHEMBL17509608 | 0.74 | GLS (0.41) | MCHR1HTR2CSLC6A4GLSHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170233335-A1 | INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF | BRYN MAWR COLLEGE | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233335-A1 | INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF | CD4, CD81, ICAM1 | MCHR1 3750/4885HTR2C 3239/4885SLC6A4 3208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.